Inflation and the Covid-19 pandemic have put pharmaceutical productivity front and center in recent years. Thus, drug companies are under mounting pressure to prove that new treatments are safe and ...
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced ...
2011–2015: C-Path gained global recognition for its trailblazing biomarker qualification work, model-informed drug development collaborations, patient-focused drug development initiatives, and ...
Simulations Plus is a specialized in silico software-and-services platform. They help with model-informed, non-animal drug development. SLP’s services help across discovery, development, and clinical ...
A frequently reported fact in the drug discovery and development industry is that approximately 90 % of drug candidates reaching clinical trials fail, with even higher amounts discarded before ...
In a recent exclusive interview, Fierce Biotech’s Chris Hayden sat down with Alex MacDonald, Vice President of Model-Informed Drug Development at Allucent, to explore the impact of Project Optimus, an ...
TUCSON, Ariz., May 8, 2025 /PRNewswire/ -- The year 2025 marks a historic milestone for Critical Path Institute ® (C-Path), as the organization celebrates 20 years of transforming the landscape of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback